Sweden approves generic copy of GSK's top lung drug
LONDON Jan 14 (Reuters) - Sweden has followed Denmark and Germany in approving the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair.
Britain's Vectura said on Tuesday its partner Sandoz, the generics division of Switzerland's Novartis , had received Swedish authorisation for its generic version of the drug, known as AirFluSal Forspiro.
The initial Danish green light was given to the product in December.
- Six people injured when camera catches fire at 30 Rockefeller Plaza
- Israel holds off on escalating Gaza barrage; West wants truce |
- Russia warns Ukraine after shell crosses border |
- Exclusive: YouTube weighs funding efforts to boost premium content - sources
- 'Excessive' rubbing of engine blades caused F-35 failure: Pentagon